MedTrace Logo

Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma

NCT06364566 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2024-04-15

No results posted yet for this study

Summary

The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma. In this study, based on previous studies, the investigators divided patients into two groups with a cutoff value of 50 days. By comparing the overall survival and disease-free survival of the entire population and non PCR population, the investigators ultimately obtained the optimal surgical timing suitable for clinical use

Conditions

  • Time

Interventions

RADIATION

Neoadjuvant chemradiotherapy

Patients receiving neoadjuvant chemradiotherapy cause tumor shrinkage

PROCEDURE

Minimally invasive esophagectomy

The patient underwent minimally invasive esophagectomy to remove residual tumors and surrounding lymph nodes

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-15
Primary Completion
2016-10-15
Completion
2019-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06364566 on ClinicalTrials.gov